At the national level, for the 2024–2025 period*:

• The participation rate among the target population is 30.7%, a slight increase from the previous period (29.6% in 2023–2024) and still below the acceptable European threshold (45%)

• The participation rate among the eligible population cannot be calculated due to the lack of aggregated data on individuals excluded from the PNDOCCR

• The proportion of individuals with an unanalyzed screening test that was not retaken is 2.8% (below the European benchmark of 3%)

• The proportion of individuals with a positive screening test is 3.4%, stable in recent years

* For this bulletin, given the current unavailability of data on individuals excluded from the PNDOCCR, only participation rates relative to the target population are presented for 2023–2024 and 2024–2025.

Access the bulletin and download the 2024–2025 participation table (xlsx – 158 KB).

• Participation by gender (PNG - 160 KB)

• Proportion of positive tests by gender (PNG - 152 KB)

• Number of participants by gender and standardized participation rates, France as a whole, by region, and by department (xls - 2.7 MB)

Santé publique France has been responsible for evaluating the performance of the national colorectal cancer screening program since its launch in 2008–2009.

This evaluation is based on data submitted annually to Santé publique France by the Regional Cancer Screening Coordination Centers (CRCDC). These data are individual and anonymized; they cover all individuals who underwent a screening test between January 1 and December 31 of the year in question. Santé publique France monitors the quality of this data. Once validated by the CRCDCs and Santé publique France, the latter compiles a national database that enables the calculation of performance evaluation indicators for the screening program. This data includes information on sociodemographic characteristics (age, sex, municipality of residence at the time of screening, social security status), history of organized screening (date of previous organized screening, number of times participating in the organized screening program), all results of the screening in question (date and result of the screening test, hemoglobin level, date and result of the colonoscopy in the event of a positive test, pathology report, and final diagnosis), and the characteristics of any lesions detected.

Data are initially transmitted two years after the year under evaluation. This timeframe allows for the collection of high-quality and as comprehensive as possible information, particularly regarding the results of examinations conducted following a positive screening result. Follow-up data for positive screenings are subsequently updated for 4 consecutive years. Consequently, the data from the last two years presented here are the most recent and are considered provisional.

The format of the reported data and all the indicators produced (proportion of positive tests, proportion of people who underwent a colonoscopy following a positive test, proportion of people who underwent a complete colonoscopy, proportion of people who underwent a colonoscopy that resulted in a complication, average time between the date of a positive screening test result and the date of colonoscopy, proportion of individuals lost to follow-up among those with a positive test, proportion of individuals who underwent a diagnostic examination with a normal result, proportion of individuals who underwent a diagnostic examination detecting at least one non-advanced adenoma/advanced adenoma/hyperplastic polyp/cancer, rate of polyps/adenomas/advanced adenomas/cancers detected per thousand screened individuals, distribution of adenocarcinomas by stage …) are described in the Guide to Data Formats and Definitions of National Program Evaluation Indicators, the first version of which was developed in 2009 by a working group comprising members of the involved institutions (DGS, Health Insurance, INCa, Santé publique France (formerly InVS), coordinating physicians from cancer screening management centers, gastroenterologists, and anatomic cytopathologists) and has been regularly updated since then.

Indicators of the quality of tests, examinations, follow-up, and lesion detection are estimated by department (where sample sizes permit), by region, and for France as a whole. They are calculated according to sex, age, and screening stage (first screening versus subsequent screenings). They are calculated over two-year periods to reflect the duration of a screening invitation campaign. The results presented for each period correspond to data from individuals who underwent a FIT test for colorectal cancer screening between January 1 of year 1 and December 31 of year 2.

• 2020–2021

  • National indicators

  • Indicators by region and department

• 2018–2019

  • National indicators

  • Indicators by region and department

• 2016–2017

  • National indicators

  • Indicators by region and department

• Period from April 14 to December 31, 2015

  • National indicators

  • Indicators by region and department

• 2013–2014

  • National indicators

  • Indicators by region and department

• 2012–2013

  • National indicators

  • Indicators by region and department

• 2011–2012

  • National indicators

  • Indicators by region and department

• 2010–2011

  • National indicators

  • Indicators by region and department

• 2009–2010

• 2008–2009